Impact of Body Size on Preclinical Type 1 Diabetes Development and Progression

Area of Science:

• Immunology
• Endocrinology
• Metabolism

Background:

• Type 1 diabetes results from genetic and environmental factors causing autoimmune beta-cell destruction.
• Current therapies for type 1 diabetes have inconsistent and temporary effects.
• Heterogeneity in type 1 diabetes necessitates understanding distinct mechanistic pathways.

Purpose of the Study:

• To investigate the role of obesity as a modifiable environmental risk factor in type 1 diabetes.
• To elucidate the biological pathways linking elevated body mass index (BMI) to autoimmune beta-cell destruction.

Main Methods:

• Analysis of data from longitudinal cohorts like The Environmental Determinants of Diabetes in the Young (TEDDY) and Type 1 Diabetes TrialNet.
• Examination of epidemiological links between BMI, adiposity, and type 1 diabetes onset and progression.
• Review of emerging data on immunologic and metabolic disturbances associated with obesity.

Main Results:

• Epidemiological data consistently link higher BMI and adiposity to increased risk of islet autoimmunity and type 1 diabetes.
• Obesity-related risk is not uniform, with increased susceptibility observed in younger children, Hispanic populations, and specific HLA genotypes.
• Emerging evidence suggests a network of insulin resistance, beta-cell stress, inflammation, altered adipokines, and gut microbiome changes contribute to disease pathogenesis.

Conclusions:

• Elevated BMI is a significant environmental factor influencing type 1 diabetes development.
• Understanding obesity-associated immunologic and metabolic pathways is crucial for developing targeted prevention strategies.
• Future research should explore interventions modifying BMI or related pathways to alter the preclinical trajectory of type 1 diabetes.